Location

Campo Mártires da Pátria, 130 | 1169-056 Lisboa

Jacinta Serpa

Professor Professor Auxiliar
Principal Investigator

Jacinta Serpa holds a Biology degree from the University of the Azores (1997) and a PhD in Human Biology, specializing in glycobiology and gastric cancer, from the University of Porto (2005). With over 20 years of experience in cancer biology, she has been a faculty member at NOVA Medical School since 2008 and a senior researcher at the Portuguese Oncology Institute (IPOLFG) since 2006.

Her research focuses on cancer metabolism, specifically the metabolic reprogramming that supports cancer cell survival in specific microenvironments and influences therapeutic response. Since 2015, she has led the Cancer Metabolism and Microenvironment Laboratory at NOVA Medical School and IPOLFG. Her work centers on identifying metabolic biomarkers linked to chemoresistance and prognosis, and discovering therapeutic targets based on tumor metabolic vulnerabilities, with metabolomics playing a crucial role. JSerpa aims to understand cancer within its pathophysiological context, uncovering key metabolic processes that drive tumor growth and resistance, contributing to the development of targeted therapies. She has published 55 peer-reviewed papers (37 as senior or corresponding author), with a significant impact reflected by an h-index of 29 and nearly 2,900 citations.

Recently, she filed a national and PCT patent for a novel therapy targeting glutamine dependence in glioblastoma, overcoming previous treatment challenges like blood-brain barrier penetration and toxicity. The international patent phase begins in March 2026. In addition to research, J Serpa is committed to teaching and academic leadership, coordinating oncology-related courses and a postgraduate program in Clinical Genetics and Genomics at NOVA Medical School.

  • Mendes C, Martins F, Granja S, Gonçalves J, Barros H, Casimiro T, Aguiar-Ricardo A, Silva F, Abreu B, Cristovão M, André S, Pereira SA, Baltazar F, Cabral-Marques H, Gaspar MM, Gonçalves LG, Bonifácio VDB, Serpa J. Metabolism-targeted therapy in NSCLC - A new theranostics inhalation approach using lactate functionalized and selenium-chrysin loaded nanoparticles (SeChry@PUREG4-LA24). Biomed Pharmacother. 2025 Sep;190:118405. doi: 10.1016/j.biopha.2025.118405.
  • Martins F, Arada R, Barros H, Matos P, Ramalho J, Ceña V, Bonifácio VDB, Gonçalves LG, Serpa J. Lactate-coated polyurea-siRNA dendriplex: a gene therapy-directed and metabolism-based strategy to impair glioblastoma (GBM). Cancer Gene Ther. 2025 Jun;32(6):690-705. doi: 10.1038/s41417-025-00906-8.
  • Ferreira B, Lemos I, Mendes C, Chumbinho B, Silva F, Pereira D, Vigia E, Gonçalves LG, Figueiredo A, Cavaco D, Serpa J. Glucagon and Glucose Availability Influence Metabolic Heterogeneity and Malignancy in Pancreatic Neuroendocrine Tumour (pNET) Cells: Novel Routes for Therapeutic Targeting. Molecules. 2025 Jun 25;30(13):2736. doi: 10.3390/molecules30132736.
  • Lemos I, Freitas-Dias C, Hipólito A, Ramalho J, Carteni F, Gonçalves LG, Mazzoleni S, Serpa J. Cell-Free DNA (cfDNA) Regulates Metabolic Remodeling in the ES-2 Ovarian Carcinoma Cell Line, Influencing Cell Proliferation, Quiescence, and Chemoresistance in a Cell-of-Origin-Specific Manner. Metabolites. 2025 Apr 2;15(4):244. doi: 10.3390/metabo15040244.
  • Lemos I, Freitas-Dias C, Hipólito A, Ramalho J, Carteni F, Gonçalves LG, Mazzoleni S, Serpa J. Cell-Free DNA (cfDNA) Regulates Metabolic Remodeling, Sustaining Proliferation, Quiescence, and Migration in MDA-MB-231, a Triple-Negative Breast Carcinoma (TNBC) Cell Line. Metabolites. 2025 Mar 27;15(4):227. doi: 10.3390/metabo15040227.
  • Mendes C, Lemos I, Hipólito A, Abreu B, Freitas-Dias C, Martins F, Pires RF, Barros H, Bonifácio VDB, Gonçalves LG, Serpa J. Metabolic profiling and combined therapeutic strategies unveil the cytotoxic potential of selenium-chrysin (SeChry) in NSCLC cells. Biosci Rep. 2024 Jul 31;44(7):BSR20240752. doi: 10.1042/BSR20240752.
  • Freitas-Dias C, Gonçalves F, Martins F, Lemos I, Gonçalves LG, Serpa J. Interaction between NSCLC Cells, CD8+ T-Cells and Immune Checkpoint Inhibitors Potentiates Coagulation and Promotes Metabolic Remodeling-New Cues on CAT-VTE. Cells. 2024 Feb 7;13(4):305. doi: 10.3390/cells13040305.
  • Hipólito A, Mendes C, Martins F, Lemos I, Francisco I, Cunha F, Almodôvar T, Albuquerque C, Gonçalves LG, Bonifácio VDB, Vicente JB, Serpa J. H2S-Synthesizing Enzymes Are Putative Determinants in Lung Cancer Management toward Personalized Medicine. Antioxidants (Basel). 2023 Dec 28;13(1):51. doi: 10.3390/antiox13010051.
  • Hipólito A, Xavier R, Brito C, Tomás A, Lemos I, Cabaço LC, Silva F, Oliva A, Barral DC, Vicente JB, Gonçalves LG, Pojo M, Serpa J. BRD9 status is a major contributor for cysteine metabolic remodeling through MST and EAAT3 modulation in malignant melanoma. Biochim Biophys Acta Mol Basis Dis. 2023 Dec 7;1870(2):166983. doi: 10.1016/j.bbadis.2023.166983
  • Nunes SC, Sousa J, Silva F, Silveira M, Guimarães A, Serpa J, Félix A, Gonçalves LG. Peripheral Blood Serum NMR Metabolomics Is a Powerful Tool to Discriminate Benign and Malignant Ovarian Tumors. Metabolites 2023, 13(9), 989; https://doi.org/10.3390/metabo13090989